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Summary
 
Over the last few years, sphingolipids have been identified as potent second messenger mole-
cules modulating cell growth and activation. A newly emerging facet to this class of lipids sug-
gests a picture where the balance between two counterregulatory lipids (as shown in the partic-
ular example of ceramide and sphingosine-1-phosphate in T lymphocyte apoptosis) determines
the cell fate by setting the stage for various protein signaling cascades. Here, we provide a fur-
ther example of such a decisive balance composed of the two lipids sphingosine and sphingo-
sine-1-phosphate that determines the allergic responsiveness of mast cells. High intracellular
concentrations of sphingosine act as a potent inhibitor of the immunoglobulin (Ig)E plus anti-
gen–mediated leukotriene synthesis and cytokine production by preventing activation of the
mitogen-activated protein kinase pathway. In contrast, high intracellular levels of sphingosine-
1-phosphate, also secreted by allergically stimulated mast cells, activate the mitogen-activated
protein kinase pathway, resulting in hexosaminidase and leukotriene release, or in combination
with ionomycin, give cytokine production. Equivalent high concentrations of sphingosine-
 
1-phosphate are dominant over sphingosine as they counteract its inhibitory potential. Therefore,
it might be inferred that sphingosine-kinase is pivotal to the activation of signaling cascades initi-
 
ated at the Fc
 
e 
 
receptor I by modulating the balance of the counterregulatory lipids.
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P
 
hosphoinositides and corresponding lipid kinases com-
prise a signaling system of increasingly known impor-
 
tance for cell survival and proliferation. This is illustrated by
 
the central role of phosphatidylinositol-3-kinase (PI-3K)
 
1
 
 in
signaling cascades initiated at receptors such as the platelet-
 
derived growth factor (PDGF) receptor, insulin receptor,
CD28, and CD40. The phospholipase C–mediated genera-
 
tion of diacylglycerol, which is a prominent example of
another lipid signaling system, leads to the activation of
classical and novel protein kinase C (PKC) isoforms, mainly
involved in differentiation and regulation of effector func-
tions (participation in T cell receptor cycling, Fas expression,
as well as IL-2 and IL-2 receptor expression [1–3]). Besides
these two well-established systems, another class of lipids,
the sphingolipids, are emerging as components of the cellu-
lar lipid signaling machinery participating in cell growth
and differentiation, oncogenic transformation, and immune
recognition and responsiveness (4–6). Sphingosine (S) itself,
the central component to this lipid mediator class, func-
 
tions as a dual modulator of cellular responses. It acts as a
potent inhibitor of PKCs, but recently activation of the re-
tinoblastoma (Rb) protein and p21-activated kinases (PAKs)
with subsequent triggering of the corresponding signaling
pathways has been described (7, 8). The seemingly conflict-
ing data on activation and repression of the same signaling
steps in different cell types by one sphingolipid are, in addi-
tion to cell type specificity and different costimuli, ex-
plained by the finding of a “lipid network.” For this hy-
pothesis, it is not the mere presence of one sphingolipid
that determines the outcome but rather its relative ratio to
other members of this mediator class. This was first sug-
gested for the intracellular balance of ceramide and sphingo-
sine-1-phosphate (S1P) in the regulation of T lymphocyte
apoptosis (9).
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Abbreviations used in this paper:
 
 BMMC, bone marrow–derived mouse
mast cell; erk, extracellular signal regulatory kinase; jnk, c-jun NH
 
2
 
-ter-
minal kinase; MAP, mitogen-activated protein; MAPK, MAP kinase;
MBP, myelin basic protein; MEK, MAPK kinase; NF-AT, nuclear factor
of activated T cell(s); PI-3K, phosphatidylinositol-3-kinase; PKC, protein
kinase C; RBL, rat basophilic leukemia; S, sphingosine; S1P, sphingo-
sine-1-phosphate; SK, S-kinase. 
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Sphingosine Phosphorylation, A Prerequisite for Mast Cell Activation
 
In the rat basophilic leukemia cell line, RBL, Fc
 
e
 
RI cross-
linking leads to S-kinase (SK) activation and conversion of
S to S1P. This compound has been demonstrated to act as an
alternative second messenger to inositol-1,4,5-trisphosphate
(IP3). Inhibition of SK by the S analogue, 
 
d
 
-
 
l
 
-threo-dihy-
drosphingosine, strongly suppresses the IgE plus antigen
(IgE/Ag)-mediated calcium influx, but has no influence on
the activation of the tyrosine kinase, syk (10). In the con-
text of the lipid network hypothesis, S and S1P can be in-
terpreted as two counterregulatory factors determining the
allergic responsiveness in RBL cells, with SK acting as a
kind of “permissive switch.”
Here, we show the effects of S and S1P on noninduced
and IgE/Ag-induced CPII mouse mast cells as well as pri-
mary bone marrow–derived mouse mast cells (BMMCs) in
an attempt to determine the influence of the SK activity on
an allergic response. In CPII cells, the early phase of mast
cell activation (degranulation) is insensitive to S applica-
tion, whereas
 
 
 
leukotriene synthesis and the transcriptional
induction of cytokines are strongly inhibited by this lipid
due to abrogation of the mitogen-activated protein kinase
(MAPK) pathway. This effect was confirmed on BMMCs
regarding the cytokine response.
 
 
 
However, shifting the
balance towards S1P leads to a restoration of the cellular re-
sponse in both cell types, demonstrating that the ratio of
these two lipids is decisive for the signal transduction events
initiated at the Fc
 
e
 
RI. This is based on the antagonistic ac-
tivity of S and S1P as inhibitor and activator of the MAPK
pathway, respectively. As a consequence of higher intracel-
lular concentrations of S1P, AP1 transcription factors are
induced in CPII cells, a response reminiscent of the AP1-
mediated cell division of Swiss 3T3 fibroblasts after S1P
treatment (11).
 
Materials and Methods
 
Transient transfections, gel shift analyses, hexosaminidase re-
lease assay, leukotriene assay, TNF-
 
a
 
 ELISA, use of ionomycin
and apigenin, Western blot analyses, preparation of radiolabeled
probes, nuclear extracts, and electrophoretic mobility shift assays
were done as described (12–16).
 
Materials.
 
S was purchased from Sigma Chemical Co. and
dissolved in DMSO at a concentration of 10 mM. S1P was pur-
chased from Calbiochem. For dissolving S1P, 2 
 
m
 
l morpholin
was used to convert 1 mg S1P to its salt before MeOH was added
to achieve a concentration of 10 mM.
 
Antibodies.
 
Antibodies for raf and MAPK kinase (MEK) 1
used in Western blot analyses were purchased from Transduction
Laboratories. Antibodies directed against extracellular signal regu-
latory kinase (erk) 1,2, c-jun NH
 
2
 
-terminal kinase (jnk) 1,2, and
p38 (phospho-specific and non–phospho-specific) come from
New England Biolabs. Supershift antibodies directed against AP1
components come from Santa Cruz Biotechnologies.
 
BMMC Generation.
 
BMMCs were generated by the method
of Rottem et al. (17). Fresh bone marrow cells were cultured in
complete RPMI 1640 supplemented with 10 ng/ml IL-3 (Pepro-
Tech) and 100 ng/ml stem cell factor (SCF; PeproTech) for at
least 2 wk. They were characterized as BMMCs by flow cytome-
try as CD45
 
1
 
, CD117
 
1
 
, CD9
 
1
 
 and positive for staining with
FITC-labeled mouse IgE but were CD90.2
 
2
 
, CD4
 
2
 
, CD8
 
2
 
,
 
CD45/B220
 
2
 
, CD11b
 
2
 
, CD11c
 
2
 
, Gr-1
 
2
 
, TER-119
 
2
 
, and
MHC class II
 
2
 
. Purity was estimated at 
 
.
 
95%. All antibodies
were FITC, PE, or biotin labeled and purchased from PharMin-
gen except for mouse IgE (clone SPE-7; Sigma Chemical Co.),
which was directly labeled with FITC Cellite (Calbiochem) and
purified over Sephadex G-25 (Amersham Pharmacia Biotech) be-
fore use. Cells were stimulated with 2 
 
m
 
g/ml murine IgE (Sigma
Chemical Co.) and 100 ng/ml DNP-BSA (Calbiochem) for the
time points indicated in the figure legends.
 
Immunoprecipitations/Kinase Assays.
 
The kinase assay for c-raf
activity was done using the c-raf 1 immunoprecipitation kinase
cascade assay kit (Upstate Biotechnology) according to the manu-
facturer’s protocol. The MEK 1 kinase activity was determined
using the MAPKK immunoprecipitation kinase cascade kit (Up-
state Biotechnology). In both cases, cells were either left unstim-
ulated or were stimulated for 7 min (raf) or 9 min (MEK) with
and without S application. Reactions were separated by SDS-
PAGE, then subjected to autoradiography.
 
Determination of Sphingolipids in Mast Cells.
 
4 
 
3
 
 10
 
5
 
 mast cells
were incubated with 10 
 
m
 
M S (Sigma Chemical Co.) containing
100 nM (2 
 
m
 
Ci) 
 
3
 
H-S (Amersham Pharmacia Biotech) for up to
4 h. Subsequently, cells or supernatants were extracted with 2 vol
CHCl
 
3
 
/methanol (1:2), sonicated, and again extracted with
CHCl
 
3
 
/KCl (2:1). After lyophilization, lipids were dissolved
in CHCl
 
3
 
 and analyzed by thin layer chromatography (
 
n
 
-butanol/
CH
 
3
 
COOH/H
 
2
 
O [6:2:2]). After drying, the plate was subjected
to autoradiography. For detection of Ser-containing lipids, 10
 
7
 
cells were incubated with 5 
 
m
 
Ci 
 
14
 
C-Ser (Amersham Pharmacia
Biotech) for 24 h. Cells were then either left unstimulated or
were stimulated with IgE/Ag. Lipids were extracted and sepa-
rated as described above. After chromatography, the plates were
subjected to autoradiography.
 
SK Assay.
 
SK activity of mast cells was determined by adding
1 
 
m
 
M and 10 
 
m
 
M S (Sigma Chemical Co.) to cell lysates (from 10
 
6
 
cells) prepared by repeated freeze–thaw cycles in kinase buffer
(50 mM Hepes, pH 7.4, 50 mM LiCl, 15 mM MgCl
 
2
 
, 15 mM
CaCl
 
2
 
, 1 mM EDTA, 1 mM EGTA, 0.2 mM PMSF, 10 
 
m
 
M
ATP). 5 
 
m
 
Ci [
 
g
 
-
 
32
 
P]ATP (Amersham Pharmacia Biotech) was
added, and the reaction was incubated at room temperature for 1 h.
Lipids were extracted and separated as described above.
 
Results
 
A Strong SK Activity Leads to a Rapid Conversion of S to
S1P in CPII Mast Cells.
 
In an in vitro kinase reaction
with exogenous S, a strong basal SK activity is detected in
cellular extracts from nonactivated CPII cells, which is
slightly induced after IgE/Ag activation, comparable to the
recently reported data on RBL cells (10). Without the ad-
dition of S, no phosphorylation is observed, suggesting that
the intracellular concentration of this lipid is normally low
in CPII cells (Fig. 1 A). This is supported by the failure to
detect S in lipid extractions of CPII cells by thin layer
chromatography either after staining with fluram (data not
shown; detection limit 
 
z
 
1 
 
3
 
 10
 
2
 
15
 
 g/cell; S content in
other cells 
 
z
 
3 
 
3
 
 10
 
2
 
14
 
 g/cell) or by autoradiography after
incubating cells with 
 
14
 
C-Ser, a precursor for cellular
sphingolipids, for 24 h. However, other Ser-containing lip-
ids are easily found by these methods (Fig. 1 B). Taken to-
gether, these findings suggest a permanent conversion of
S to S1P. In vivo, this conversion is visualized by the addi- 
3
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tion of 100 nM 
 
3
 
H-S to CPII cells. Within 10 min of incu-
bation, S is converted to S1P and a further degradation
product (phosphoethanolamine; Fig. 1 C, left). Overloading
the cellular machinery by applying 10 
 
m
 
M S in vivo leads
to a delay of both the phosphorylation and degradation, re-
sulting in considerable levels of internal S present up to 4 h
in nonstimulated as well as IgE/Ag-stimulated cells (Fig. 1 C,
middle and right).
 
High Levels of Intracellular S Prevent Leukotriene Synthesis
and Cytokine Transcription.
 
To investigate if the accumula-
tion of S affects the allergic responsiveness of CPII mast
cells, readouts measuring the degranulation (hexosaminidase
release assay), leukotriene synthesis (ELISA), and cytokine
transcription (reporter gene assays) were performed. The
IgE/Ag-mediated degranulation reaction was, if at all, only
marginally inhibited by 10 
 
m
 
M S (Fig. 2 A). However, leu-
kotriene synthesis, as well as the transcriptional activation
of IL-5 and TNF-
 
a
 
 that is usually seen in CPII cells after
IgE/Ag activation, was dramatically reduced (Fig. 2, B and
C). This indicates that high intracellular concentrations of S
specifically abrogate signaling cascades essential for the in-
duction of these mediators.
 
S Is a Potent Inhibitor of the MAPK Pathways in IgE/Ag-
stimulated CPII Cells.
 
PMA-dependent PKCs, the prime
targets for inhibition by lysosphingolipids, are known to be
dispensable for the induction of TNF-
 
a
 
 in CPII cells after
Fc
 
e
 
RI triggering (16). The production of this cytokine and
leukotriene synthesis strongly depend on the activation of
the MAPK pathway, suggesting that this signaling cascade
is a previously unrecognized target for S-mediated modula-
 
tion (18). 1-h treatment with 10 
 
m
 
M S before IgE/Ag acti-
vation prevented the 50–100-fold enhancement of the raf
and MEK kinase activity, measured in in vitro kinase reac-
tions of immunoprecipitates using myelin basic protein
(MBP) as a readout (Fig. 3, A and B). Subsequently, the
two IgE/Ag-responsive MAPKs in CPII cells, erk 1,2 and
jnk 1, are hypophosphorylated, as measured in a Western
blot analysis (pThr 202/pTyr 204 and pThr 183/pTyr 185;
Fig. 3, C and D). This shows that the inhibitory potential
of S affects all MAPK pathways that are induced in mast
cells after IgE/Ag stimulation (16).
 
AP1-mediated Transcription Is Prevented by S.
 
The lack of
MAPK activity results in a strongly reduced phosphoryla-
tion of the AP1 component, c-jun, one of the targets of
jnk1 at the transcription factor level (Fig. 4 A). As a conse-
quence, AP1 transcriptional activity (3 x TRE reporter
gene plasmid) is reduced compared with stimulated cells
without S treatment, as shown by transient transfections
(Fig. 4 B). This explains the inhibition observed for the
transcription of TNF-
 
a
 
, which strongly depends on AP1
serving as a cofactor for nuclear factor of activated T cells
(NF-AT) at the 
 
k
 
3 site of the promoter in CPII cells (16).
 
The Effect of S Is Prevented by Equimolar Concentrations of
S1P.
 
At this point, we speculated that the internal bal-
ance of S and S1P is a kind of permissive switch that might
determine the potential of mast cells to respond to Fc
 
e
 
RI
triggering. In this hypothesis, it is not the overall concen-
tration of S but rather the relative ratio of S to its derivative
S1P that would be decisive for initiating a response. To test
this, we incubated CPII cells with equimolar amounts of S
Figure 1. A strong SK activity mediates
the rapid degradation of S in CPII mast
cells. (A) Determination of SK activity of ei-
ther nonstimulated (nst) or 2 min–stimu-
lated (IgE/Ag) CPII cells. 2, reactions
without exogenous S. The position of S1P
on the thin layer plate is indicated by an ar-
row (right). (B) Ser-containing lipids from
nonstimulated (nst) or stimulated (IgE/Ag)
CPII cells. The position of S, which served
as a standard (Std), is indicated by an arrow
(right). (C) S phosphorylation and degrada-
tion (100 nM or 10 mM as indicated) after incubating nonstimulated and stimulated cells (indicated at the bottom) for various time points (top). 2, non-
stimulated cells. Stimulated cells were preincubated with S for 1 h before stimulation. S served as a standard (Std); d, degradation product. The positions
of S, S1P, and the degradation product are indicated by arrows (right).
Figure 2. High levels of intracellular S
strongly inhibit leukotriene synthesis and cy-
tokine transcription. Cells were either left un-
stimulated (nst) or were pretreated with sol-
vent before activation with IgE/Ag (IgE/Ag)
or pretreated with S (IgE/Ag 1 S) for 1 h
before activation with IgE/Ag. (A) Hexo-
saminidase release as indicated on the y-axis.
Stimulation conditions are given on the x-axis.
Values represent mean of quadruplicate ex-
periments  6  SD. (B) Leukotriene (LT) release
as indicated on the y-axis (in pg/ml LT).
Stimulation conditions are given on the x-axis.
Values represent mean of quadruplicate ex-
periments  6  SD. (C) The transcriptional acti-
vation of IL-5 and TNF-a was determined in a reporter gene assay after transient transfections. pGL2 represents the parental vector. Corrected luciferase
values are given on the y-axis; stimulation conditions and input DNA are indicated on the x-axis. Data represent mean 6 SD of triplicate determinations. 
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and S1P (10 
 
m
 
M) for 1 h before IgE/Ag stimulation. Un-
der these conditions, the transcriptional activation of TNF-
 
a
 
can be restored to 
 
z
 
60% of IgE/Ag-induced levels (Fig.
5 A). The ability of S1P to decisively overcome the S-medi-
ated inhibition is not due to the fact that less S is present in
the cells (shown by uptake experiments with 
 
3
 
H-S), but
rather suggests that S1P is an activation molecule, as already
proven for other cell types (10, 19–21; Fig. 5 B).
 
Effects of S and S1P on BMMCs.
 
To confirm the gen-
eral applicability of the hypothesis that the balance between
S and S1P is decisive for activation of mast cells via the
Fc
 
e
 
RI, we generated BMMCs and repeated several key ex-
periments. Addressing the fact that there was a lack of S in
nonstimulated CPII cells, which we speculated to be a par-
ticular characteristic of our cell line, we investigated the
composition of Ser-containing lipids in nonstimulated as
well as 1-h IgE/Ag-stimulated BMMCs after incubation
with 
 
14
 
C-Ser for 24 h (Fig. 6 A). In both cases, internal S is
readily detectable with a slightly reduced concentration in
induced cells. Complementary to this reduction, an in vitro
kinase reaction demonstrates a strongly inducible, but judged
from the exposure time and input concentration of exoge-
nous S, much weaker SK activity in stimulated BMMCs
compared with CPII cells (Fig. 6 B). This weaker SK activ-
ity also results in no detectable conversion of endogenous S
in this experimental setup, and is further demonstrated by
uptake experiments with 100 nM and 10 
 
m
 
M S shown in
Fig. 6 C. Compared with CPII cells, BMMCs show a re-
duced phosphorylation rate and a delayed conversion of S
to S1P and the degradation product (phosphoethanolamine),
whether with a 100 nM or a 10 
 
m
 
M S application (com-
pare Fig. 6 C with Fig. 1 C). However, in agreement with
the inducible SK activity in these cells, there is a more rapid
and pronounced phosphorylation of S seen in IgE/Ag-stim-
ulated cells (Fig. 6 C). As in CPII cells, the high intracellu-
lar concentration of S, if 10 mM is applied, leads to a strong
inhibition of the IgE/Ag-inducible production of TNF-a
as measured in a corresponding ELISA. This effect is par-
tially reversible by applying an equivalent amount of S1P,
even though it is not as strong as that observed in the CPII
cell line (Fig. 6 D). This is most likely due to the fact that
Figure 3. S inhibits the MAPK pathways. Cells were either left unstimu-
lated (nst) or were pretreated with solvent before activation with IgE/Ag
(IgE/Ag) or pretreated with S (IgE/Ag 1 S) for 1 h before activation with
IgE/Ag. (A) Raf kinase activity was determined after immunoprecipita-
tions. MBP was used as substrate (indicated by an arrow). Reactions were
separated by SDS-PAGE. Western blots of the immunoprecipitate for nor-
malization are shown below (raf IP, indicated by an arrow). (B) MEK 1 ac-
tivity was determined after immunoprecipitations. MBP was used as a sub-
strate (indicated by an arrow). Reactions were separated by SDS-PAGE.
Western blots of the immunoprecipitate for normalization are shown below
(MEK 1 IP, indicated by an arrow) (C) Western blots to investigate erk 1,2
activation/phosphorylation. Cells were activated for 10 min. erk 1,2 and
phospho-erk 1,2 are indicated by arrows (right). (D) Western blots for jnk
1,2 activation/phosphorylation. Cells were stimulated for 10 min. jnk 1,2
and phospho-jnk 1 are indicated by arrows (right).
Figure 4. AP1 transcription is prevented by S. (A) Western blots for
c-jun activation/phosphorylation were performed with lysates of either
nonstimulated (nst), 1 h–stimulated (IgE/Ag), or 1 h S-pretreated cells
before activation (IgE/Ag 1 S). c-jun and phospho-c-jun are indicated
by arrows (right). (B) The transcriptional activation of an AP1-dependent
reporter gene (3 x TRE) was measured in transient transfections. Cor-
rected luciferase values are indicated on the y-axis, stimuli and input
DNA on the x-axis. pGL2 represents the parental vector. Cells were acti-
vated for 3 h. Data represent mean 6 SD of triplicate determinations.
Figure 5. S1P reverts S inhibition of TNF-a. (A) The transcriptional
activation of a TNF-a reporter gene construct was determined in tran-
sient transfections. Corrected luciferase values are indicated on the y-axis,
stimulation conditions on the x-axis. Cells were either left unstimulated
(nst) or were pretreated with solvent, 10 mM S (S), or 10 mM S plus 10 mM
S1P (S 1 S1P) before activation with IgE/Ag. Data represent mean 6 SD
of triplicate determinations. (B) Determination of S in stimulated cells
(time points are given above the panels; 2, nonstimulated cells) incubated
either with S alone or S plus S1P as indicated at the top by thin layer
chromatography. The positions of S, S1P, and degradation product (d) are
indicated with arrows (right). S served as standard (Std).5 Prieschl et al.
BMMCs contain substantial intracellular concentrations of
S, and that the constitutive and induced conversion to S1P
is much slower in BMMCs compared with CPII cells. To
conclusively demonstrate that in BMMCs S abrogates the
MAPK pathway, Western blot analyses were performed to
determine the phosphorylation status of erk 1,2 in both 10-
min IgE/Ag-stimulated and S-pretreated IgE/Ag-stimu-
lated cells. Comparable to CPII cells, phosphorylated erk
1,2 was detected in induced cells, whereas S pretreatment
strongly prevents the kinase from being activated without
affecting its constitutive expression (Fig. 6 E).
S1P Leads to Mast Cell Degranulation, Stimulation of Leu-
kotriene Synthesis, and Activation of the MAPK Pathways.
To address the molecular mechanism by which S1P over-
comes the S-mediated inhibition, we again used CPII cells
as a model system. In these cells, application of S1P resulted
in a direct dose-dependent release of hexosaminidase and
leukotriene synthesis (Fig. 7, A and B). In addition, the
transcriptional induction of TNF-a is induced if S1P is
added together with ionomycin, but not with PMA (Fig.
7 C). Taken together, these data suggest that S1P acts con-
trary to S, mediating the activation of the MAPK pathways.
To prove this hypothesis, Western blot analyses were
performed measuring the phosphorylation of the MAPK
pathway components MEK 1,2, erk 1,2, and jnk 1, which
are required for TNF-a induction after IgE/Ag triggering
(16). 5 min after S1P treatment, phosphorylation/activation
of these kinases was detected (Fig. 8 A). This leads to the
subsequent enhancement in the phosphorylation of c-jun
and the assembly of several AP1 proteins on a consensus
binding site as demonstrated by a supershift analysis (Fig. 8,
A and B). The composition of the complex is similar to the
complex observed after IgE/Ag stimulation. In both set-
tings, binding of fosB, c-fos, c-jun, and junD was observed
(22). Therefore, a combination of S1P and Ca21 iono-
phores allows the activation of AP1 and NF-AT, which
synergistically mediates TNF-a transcription (16).
Allergically Activated Mast Cells Release S1P into the Superna-
tant. Recent reports indicated that activated platelets secrete
S1P (23). Therefore, we tested supernatants of nonstimulated
and IgE/Ag-stimulated CPII cells for the presence of sphin-
golipids by labeling with 14C-Ser and 3H-S. In both settings,
secretion of S1P by CPII cells was demonstrated after 2- and
4-h IgE/Ag triggering (Fig. 9, A and B). The same results
were obtained if supernatants of IgE/Ag-stimulated BMMCs
labeled with 14C-Ser were tested (Fig. 9 C). Matching the lack
of endogenous S in CPII cells, this lipid was also not found in
the supernatants of allergically triggered cells. However, IgE/
Ag-activated BMMCs do not release S into the supernatant,
although it is easily detectable intracellularly (Fig. 9, A and C).
These findings, together with the delayed appearance of S1P
in the supernatant, strongly suggest an active secretion of this
mediator rather than its being a by-product of the degranula-
tion reaction or the result of passive diffusion of this lipid. This
implies that only an activating factor is released. To further
highlight the physiological relevance for this secretion process,
we tested BMMCs for their ability to respond to S1P. Similar
to CPII cells (compare Fig. 7 A), there was a dose-dependent
degranulation of primary mast cells as observed in a hex-
osaminidase release assay, suggesting that an immunecomplex-
independent amplification process of early allergic reactions via
released S1P could occur (Fig. 9 D).
Figure 6. Effects of S and S1P on BMMCs. (A) Ser-containing lipids
from nonstimulated (nst) or 1 h–stimulated (IgE/Ag) BMMCs. The posi-
tion of S, which served as a standard (Std), is indicated by an arrow
(right). (B) Determination of SK activity of either nonstimulated (nst) or
2 min–stimulated (IgE/Ag) BMMCs. 2, reactions without exogenous S.
The position of S1P on the thin layer chromatography plate is indicated
by an arrow (right). (C) S phosphorylation and degradation (100 nM or
10 mM as indicated) after incubating nonstimulated and stimulated cells
(indicated at the bottom) for various time points (top); 2, nonstimulated
cells. Stimulated cells were preincubated with S for 1 h before stimula-
tion. S served as a standard (Std); d, degradation product. The positions of
S, S1P, and the degradation product are indicated by arrows (right). (D)
The secretion of TNF-a by BMMCs was determined by a corresponding
ELISA. pg/ml TNF-a are indicated on the y-axis, stimulation conditions
on the x-axis. Cells were either left unstimulated (nst) or were pretreated
with solvent, 10 mM S (S), or 10 mM S plus 10 mM S1P (S 1 S1P) before
activation with IgE/Ag for 6 h. Data represent mean 6 SD of quadrupli-
cate determinations. (E) Western blots to investigate erk 1,2 activation/
phosphorylation. Cells were activated for 10 min. erk 1,2 and p-erk 1,2
are indicated by arrows (right).6 Sphingosine Phosphorylation, A Prerequisite for Mast Cell Activation
Discussion
The linkage of the FceRI to SK in RBL cells and our
data in the CPII mast cell system as well as primary cells are
in line with the assumption that allergic responsiveness of
these effector cells is under the control of the exact intra-
cellular balance of S and S1P (10). In this hypothesis, SK
would constitute a kind of permissive switch initiated at the
FceRI or being active constitutively, that generates an in-
tracellular lipid milieu, allowing protein-based signaling
cascades such as MAPKs and PKCs to fully activate these
effector cells. However, an alternative explanation for our
finding might be a receptor-mediated triggering of a so far
unknown signaling cascade by S1P, thereby overcoming
the intracellular-mediated inhibition by S. This hypothesis
is supported by the recent finding that S1P binds to its
receptor, endothelial differentiation gene 1 (EDG-1), and
thereby extracellularly leads to the activation of MAPKs, a
response also observed in CPII mouse mast cells after S1P
treatment (24). Contrary to this receptor-mediated effect of
S1P argues the extremely fast activation of all the MAPKs
tested, which in comparison to an FceRI activation is three
times more rapid. In addition, CPII cells respond with a simi-
lar but slightly lower increase in the intracellular Ca21
concentration than after FceRI triggering (data not shown),
which recently was shown to be independent of the presence
of EDG-1 and mediated exclusively by an increase in intra-
Figure 7. S1P is an activator of
CPII mast cells. (A) Hexosaminidase
release assay with either nonstimu-
lated (nst) or 1 h–stimulated cells.
Hexosaminidase values are indicated
on the y-axis, stimuli on the x-axis.
Values represent mean of quadrupli-
cate experiments 6 SD. (B) Leuko-
triene (LT) release of nonstimulated
(nst) or 4 h–stimulated cells. pg/ml LT
are indicated on the y-axis, stimuli on
the x-axis. Data represent mean of
quadruplicate determinations 6 SD.
(C) TNF-a reporter gene assay. Cells
were either left unstimulated (nst) or
were pretreated with solvent before stimulation with IgE/Ag, or stimulated with 10 mM S1P, 100 ng/ml ionomycin, and 20 ng/ml PMA. Data repre-
sent mean 6 SD of triplicate determinations. Luciferase values are indicated on the y-axis, stimuli on the x-axis.
Figure 8. S1P induces the MAPK pathway and AP1 transcription fac-
tors. (A) Western blot analysis with lysates of nonstimulated (nst) or 10 mM
S1P–stimulated cells for the time points indicated. MEK 1,2, phospho-
MEK 1,2, erk 1,2, p-erk 1,2, jnk 1,2, p-jnk 1, c-jun, and p-c-jun are in-
dicated by arrows (right). (B) Supershift analysis on an AP1 consensus site
as radiolabeled probe with nuclear extracts of either nonstimulated (nst)
or 1 h S1P–stimulated cells as indicated at the top. f, free probe. Antibod-
ies against AP1 transcription factors are given at the top. 2, activated
complex without antibody.
Figure 9. Activated mast cells secrete S1P. (A) Lipids detected in the
supernatants of nonstimulated (nst) or stimulated (IgE/Ag) CPII cells that
were fed with 14C-Ser for 24 h. After extraction, lipids were separated by
thin layer chromatography. S and S1P served as standard (Std); the posi-
tions of S, S1P, and the degradation product (d) are indicated by arrows
(right). (B) Sphingolipids detected in supernatants of nonstimulated or
stimulated (IgE/Ag) CPII cells that were fed with 3H-S for 1 h before ac-
tivation. Time points of activation are indicated at the top; control is the
cellular content of sphingolipids. S and S1P served as standard. The posi-
tions of S, S1P, and the degradation product (d) are indicated by arrows
(right). (C) Lipids detected in the supernatants of nonstimulated (nst) or
stimulated (IgE/Ag) BMMCs that were fed with 14C-Ser for 24 h. After
extraction, lipids were separated by thin layer chromatography. S and S1P
served as standard (Std); the positions of S, S1P, and the degradation
product (d) are indicated by arrows (right). (D) Hexosaminidase release
assay with either nonstimulated (nst) or 1 h–stimulated BMMCs. Hex-
osaminidase values are indicated on the y-axis, stimuli on the x-axis. Val-
ues represent mean of quadruplicate experiments 6 SD.7 Prieschl et al.
cellular S1P (25). Despite this increase of the intracellular Ca21
concentration after S1P treatment, TNF-a transcription and
secretion are only observed when ionomycin is added simul-
taneously as a further stimulus. The synergistic effects of S1P
and ionomycin are explained by the dependence of TNF-a
transcription on the activation of the transcription factors AP1
and NF-AT, which together form a complex at the k3 site of
this cytokine promoter (12). Ionomycin but not S1P pro-
vokes the required extracellular Ca21 influx necessary for the
activation of the Ca21-dependent phosphatase calcineurin
and the dephosphorylation and translocation of NF-AT to
the nucleus. In contrast, the AP1 components are fully acti-
vated by S1P alone, which is in line with its activation of the
MAPK pathway. A similar observation has been made for
sphingosylphosphocholine and the activation of AP1 in Swiss
3T3 fibroblasts resulting in enhanced proliferation (26).
Initially, S was described as a potent inhibitor of PKC
isozymes in vitro if applied at a concentration of z100 mM.
However, in cell cultures, specific effects of this lipid are al-
ready observed at concentrations ,10 mM, resulting in both
activation and inhibition of particular cellular functions (27,
28). The diverse spectrum of these reactions as well as the
10-fold lower concentration to provoke those reactions a
priori suggest further targets besides PKCs for this lipid. This
is illustrated further by the fact that related cell types such as
Th1 and Th2 cells respond in an opposite manner to S. The
synthesis of IFN-g is strongly inhibited in Th1 cells, whereas
IL-4 production is augmented by S in Th2 cells. An inverse
relationship is seen in these two cell types regarding DNA
synthesis, which is repressed by S in Th2 cells but not in Th1
cells (29). Mast cells, although similar to Th2 cells with re-
spect to cytokine profile, react with a strong inhibition of
their cytokine transcription and secretion, mimicking the in-
hibition of IFN-g in Th1 cells (30). Taken together, these
data suggest that there must be fundamental cell type/sub-
type–specific differences that cannot be explained by our
current knowledge of common signaling pathways in cell
types such as PKCs, MAPKs, PI-3K, and others. Different
constitutive and inducible SK activities in the different cell
types and the presence and concentration of further sphin-
golipids with counterregulatory potentials may be responsi-
ble for the diverse outcome after S treatment.
In allergically activated mouse mast cells, it was identified
that MAPK pathways are one of the common “protein-
based signaling cascades” that are sensitive to high intracel-
lular concentrations of S. Based on this finding and the
concentration of S applied, we favor the idea that many of
the inhibitory effects of S described in the literature are due
to this potential to inhibit MAPKs and not due to their
PKC inhibitory potential, which is usually seen at much
higher concentrations. Already at the level of raf, a clear
abrogation of signaling is observed leading to subsequent
hypophosphorylation of downstream kinases and dimin-
ished phosphorylation and expression of transcription fac-
tors such as c-jun. This suggests that the inhibitory event is
relatively proximal to the receptor, whereas the finding that
degranulation, which is PI-3-kinase dependent, is unaf-
fected rules out a central block at the FceRI receptor. This
assumption is in agreement with the finding by J.P. Kinet
and colleagues that the S analogue d-l-threo-dihydro-
sphingosine has no influence on syk activity (10).
The secretion of S1P by IgE/Ag-activated mast cells adds
this lipid to a variety of mediators that are released during an
allergic reaction. By using a variety of inhibitors of different
signaling cascades, such as Gö6976, FK506, dimethoxy-
viridine, and 49,5,7-trihydroflavone, to investigate which
processes S1P secretion is dependent on, only the latter sub-
stance showed any effect. However, the same drug also low-
ers endogenous S1P levels, therefore suggesting an indirect
inhibition of S1P secretion (data not shown). The ability of
S1P to activate besides mast cells, monocytes and endothelial
cells, and to mediate lymphocyte infiltration implies that it
augments the allergic reaction on a broader scale (25, 31, 32).
However, the control of signaling processes by two or
more antagonistic lipids as exemplified by our study with S
and S1P is not restricted to FceRI triggering, mast cells, or
this lipid combination (S, S1P), as demonstrated by a number
of recent reports. Fas-initiated signaling depends on the bal-
ance of ceramide and S1P in T lymphocytes (9). The same
regulatory principle applies for the ceramide- and detach-
ment-induced apoptosis that can be reverted by S1P in the
monocytic cell line U937 (20, 33). In HL-60 cells, this rever-
sion was demonstrated to be due to a shift in the activation of
the two MAPKs erk 1,2 and jnk 1,2. Although ceramide me-
diates the phosphorylation of the latter, S1P not only stimu-
lates erk 1,2 but also represses jnk 1,2 in this specific cell type
(20). This difference from the situation in CPII cells, where
both branches of MAPKs are activated by S1P, indicates that
a particular lipid has no specifically assigned function per se
but that its action strongly depends on the context.
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